FY2025 EPS Estimates for MacroGenics Increased by Analyst

MacroGenics, Inc. (NASDAQ:MGNX) – Equities researchers at Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for shares of MacroGenics in a research report issued on Wednesday, November 12th. Leerink Partnrs analyst J. Chang now anticipates that the biopharmaceutical company will earn ($1.33) per share for the year, up from their prior forecast of ($2.29). The consensus estimate for MacroGenics’ current full-year earnings is ($1.06) per share. Leerink Partnrs also issued estimates for MacroGenics’ Q4 2025 earnings at ($0.37) EPS and FY2026 earnings at ($0.74) EPS.

MacroGenics (NASDAQ:MGNX) last announced its earnings results on Wednesday, November 12th. The biopharmaceutical company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.75. The business had revenue of $72.84 million during the quarter, compared to the consensus estimate of $28.72 million. MacroGenics had a negative net margin of 21.99% and a negative return on equity of 40.24%.

MGNX has been the subject of a number of other research reports. Barclays started coverage on shares of MacroGenics in a research report on Wednesday, September 17th. They set an “overweight” rating and a $3.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of MacroGenics in a report on Wednesday, October 8th. Wall Street Zen cut MacroGenics from a “hold” rating to a “sell” rating in a research report on Saturday, August 2nd. Leerink Partners dropped their target price on MacroGenics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Friday, August 15th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $2.00 price target on shares of MacroGenics in a research note on Monday, November 3rd. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $3.60.

MacroGenics Stock Performance

NASDAQ:MGNX opened at $1.51 on Monday. The company’s 50-day simple moving average is $1.66 and its 200-day simple moving average is $1.59. MacroGenics has a fifty-two week low of $0.99 and a fifty-two week high of $3.77. The stock has a market capitalization of $95.44 million, a P/E ratio of -2.65 and a beta of 1.55.

Institutional Trading of MacroGenics

Several large investors have recently added to or reduced their stakes in the company. Quadrature Capital Ltd acquired a new position in shares of MacroGenics in the second quarter valued at about $26,000. State of Wyoming acquired a new stake in shares of MacroGenics during the first quarter worth about $28,000. Engineers Gate Manager LP purchased a new stake in MacroGenics in the second quarter valued at approximately $28,000. SG Americas Securities LLC increased its holdings in MacroGenics by 55.9% in the 3rd quarter. SG Americas Securities LLC now owns 17,179 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 6,161 shares during the period. Finally, Walleye Capital LLC purchased a new position in MacroGenics during the 2nd quarter worth approximately $30,000. Hedge funds and other institutional investors own 96.89% of the company’s stock.

Insider Activity

In other news, Director William K. Heiden bought 49,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were purchased at an average cost of $1.49 per share, with a total value of $73,755.00. Following the transaction, the director directly owned 111,000 shares in the company, valued at approximately $165,390. The trade was a 80.49% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 13.00% of the stock is currently owned by insiders.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.